Management of COVID-19 Coagulopathy in a Patient with Severe Haemophilia A.
Acta Haematol
; 144(3): 319-321, 2021.
Article
in English
| MEDLINE | ID: covidwho-802601
ABSTRACT
A 54-year-old man with a long history of severe haemophilia A treated prophylactically with efmoroctocog alpha (3,000 IU twice weekly) was diagnosed with COVID-19 infection. He had multiple risk factors for COVID-19 severity including obesity, diabetes mellitus and hypertension. He required prolonged intensive care unit (ICU) stay due to the severity of respiratory failure until his death on day 24. During his ICU stay, he received a continuous infusion of efmoroctocog alpha in order to maintain factor VIII activity between 80 and 100%, together with therapeutic doses of low-molecular-weight heparin targeting anti-Xa activity above 0.5 IU/mol. He tolerated numerous invasive procedures without bleeding. At post-mortem examination, there was no evidence for thrombosis or haemorrhage in the different organs.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Recombinant Fusion Proteins
/
Factor VIII
/
Immunoglobulin Fc Fragments
/
Heparin, Low-Molecular-Weight
/
COVID-19
/
Hemophilia A
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Acta Haematol
Year:
2021
Document Type:
Article
Affiliation country:
000510591
Similar
MEDLINE
...
LILACS
LIS